[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Immuneering Corp posts on X about $imrx, live from, promising, vienna the most. They currently have XXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Social category influence exchanges XXXX% travel destinations XXXX% stocks XXXX%
Social topic influence $imrx #2, live from 9.09%, promising 9.09%, vienna 9.09%, momentum 9.09%, $200m 9.09%, $25m 9.09%, sanofi XXXX%
Top accounts mentioned or mentioned by @nasdaqexchange @biotechtv @forbes @thealexknapp @benzeskind @bradloncar @immuneerings @targetedonc @sdbjnews @pharmexec @mainz058 @mrgat23
Top assets mentioned Sanofi (SNY)
Top posts by engagements in the last XX hours
"Were proud to be a 2025 #ScripAwards finalist as Best Oncology R&D Advance for our Phase 2a trial of atebimetinib in pancreatic cancer This honor reflects our commitment to advancing new treatments that aim to help patients live longer & feel better. #Oncology #CancerResearch"
X Link @Immuneering 2025-10-07T16:00Z XXX followers, XXX engagements
"$IMRX and @BenZeskind were honored to join @bradloncar and @BiotechTV live from the NYSE to discuss our latest progress in oncology including promising pancreatic cancer data and our deep cyclic inhibitors. Watch the full video here:"
X Link @Immuneering 2025-10-10T15:34Z XXX followers, XXX engagements
"Meet us in Vienna during #BIOEurope taking place Nov 3-5 Our CBO E.B. Brakewood will be onsite to meet with global business leaders and industry experts in the biotech & pharma fields. Learn more about $IMRX and our pipeline:"
X Link @Immuneering 2025-10-13T16:00Z XXX followers, XXX engagements
"Our clinical data featured in @TargetedOnc highlight the potential of our investigational therapy atebimetinib in combination with chemotherapy to help address pancreatic cancer an area of urgent unmet need"
X Link @Immuneering 2025-10-09T16:00Z XXX followers, XXX engagements
"ICYMI: $IMRX ended Sept. with strong momentum: XX% 9-month survival in 1L pancreatic cancer (atebimetinib + mGnP) and a $200M financing including $25M from Sanofi. Webcast replay:"
X Link @Immuneering 2025-10-15T15:20Z XXX followers, XXX engagements